Montelukast Warning Upgraded
WASHINGTON — Concerned about “continued reports of suicide” and other neuropsychiatric events among users of the allergy and asthma drug montelukast (Singulair), the FDA is moving previous warnings about these risks into a black box, the agency said Wednesday. “The boxed warning advises health care providers to avoid prescribing montelukast …
News story posted on 2020-03-04T22:19:00.0000000Z
